Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio ConditionsNews DeskMarch 1, 20260 When Novartis agreed to buy RNA therapies developer Avidity Biosciences last fall, the companies said the plan was to spin…